Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
about
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatmentProteomic-Based Approaches for the Study of Cytokines in Lung CancerProgress in systemic therapy of advanced hepatocellular carcinomaThe efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysisMechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancerTackling ALK in non-small cell lung cancer: the role of novel inhibitorsNew targeted treatments for non-small-cell lung cancer - role of nivolumabPD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?The role of pembrolizumab in the treatment of advanced non-small cell lung cancerCurrent status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyEmerging molecular classifications and therapeutic implications for gastric cancerLymphocyte-activation gene-3, an important immune checkpoint in cancerHigh-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint TracersPD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune ResponsesToxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trialsSpotlight on pembrolizumab in non-small cell lung cancer: the evidence to dateFocus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLCRecent Advances in Immunotherapy in Metastatic NSCLCEmerging therapeutic agents for lung cancerSecond- and third-generation ALK inhibitors for non-small cell lung cancerUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsCross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatmentCheckpoint inhibitors in lung cancer: latest developments and clinical potentialCurrent Status and Perspective of Immunotherapy in Gastrointestinal CancersAdvances in Cancer Immunotherapy in Solid TumorsImmune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.Lung cancer in Brazil: epidemiology and treatment challenges.Bilateral Anterior Uveitis Associated with Nivolumab Therapy.Real-world data on nivolumab treatment of non-small cell lung cancer.Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data.A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.Immune checkpoint blockade for hematologic malignancies: a reviewCurrent state of immunotherapy for non-small cell lung cancer.Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumorsImmunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancerNew developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodesInflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
P2860
Q26738359-6AE09D99-0A93-41DC-B54F-376155022F2CQ26738539-9D741714-42C6-4F81-8966-5D1DAEA0110EQ26740217-F485D4D4-6EEE-4101-8D89-C450147633FBQ26740280-31FFE6C5-6786-42E5-8B18-0D4D052345D0Q26740288-5ACE5C51-7696-4337-B409-26F426D3C9DAQ26740329-6531AA1B-4A3C-4773-AA9F-C3F33252085BQ26740988-5A4420DE-900D-4922-9248-4BB975C0FA2CQ26741101-AEB18D9C-D01B-4897-A93F-76760BC5CF92Q26742047-B8B1867B-A3D1-4C85-B7EB-FA1C0B7CD2F6Q26744076-95DCB77C-CF38-4293-9156-F2C3AE3BAAE3Q26745516-BEBB687B-8C51-447A-B448-557F8F52D107Q26745525-B3B7DCBB-5110-4DE5-AE9E-8D97F805B91DQ26746209-720408BB-33C4-4758-91C7-CBF0BCAD3F72Q27300777-A8155AD2-0D43-4220-9BC4-7FA62BFAE42CQ28067141-1DED7E09-6541-44F5-9D30-1D21F61F1697Q28067583-531641D8-ECA9-44A8-9450-D3479F5CA7B9Q28067610-35C0077D-532C-4015-B5C2-42195F26E229Q28068643-BC91C3B8-2789-425A-942E-54A21268F733Q28069323-E25CD4B7-BFE3-4BB7-9805-6B5C1EEF6FBAQ28070165-A5330E01-F3A3-481E-A3BD-5E9452D8516AQ28072496-BA4416FD-7CF4-41C3-8DB5-D368B2B23238Q28075291-DBD9AA0D-9373-43A1-B59C-EF1B40AA7931Q28076294-91232873-8070-4DFE-8B55-084ECF9F5C22Q28076467-DD6B5C17-B3AF-42F3-AD2E-4CE5604D70D3Q28076970-7CBFEE13-6D98-4556-ABA1-8CF96EC04DB3Q28080113-1D4206B7-C2B1-442C-A2B6-85CD34431B55Q30235360-2EB38F9C-78CE-4405-A66C-28670BE7B70BQ30235908-03B74CAA-78A3-4DB6-A960-BCCD148B76CFQ30275991-6B095937-ECC9-4360-9FB3-2726A315E187Q31145059-7A0CC061-C4F0-45E7-9B81-1F94A40E5381Q31171172-196C3149-3CFE-47B8-A99B-F3D74DBCD5C7Q33435236-50C86AD6-6671-4D23-82F5-8A3CF0749BFFQ33571115-536CBDD5-A7A5-405E-94D3-2DB404731AFBQ33645590-946A913E-C1DC-4F02-8546-DAE468F2A99CQ33645595-A6E48FCF-E855-4A3B-A0D0-73F91B95B6AAQ33645601-300DFA5E-7668-44E6-A763-1A4BEB5FBFABQ33645624-AB9A3846-D0A9-4274-9D8A-E6FA45956A92Q33704088-054EF7B1-8528-4373-B0EE-5FF42E84043FQ33718731-C79CADB6-9F3D-4A1D-99FF-5765D6D8348AQ33793552-3A0BF5DA-A654-438B-8D3D-EC8425384544
P2860
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Pembrolizumab versus docetaxel ...... a randomised controlled trial.
@en
type
label
Pembrolizumab versus docetaxel ...... a randomised controlled trial.
@en
prefLabel
Pembrolizumab versus docetaxel ...... a randomised controlled trial.
@en
P2093
P50
P1433
P1476
Pembrolizumab versus docetaxel ...... a randomised controlled trial.
@en
P2093
Catherine Dubos Arvis
Dong-Wan Kim
Edward B Garon
Gilberto de Castro
Gregory M Lubiniecki
Ji-Youn Han
Joo-Hang Kim
Julian Molina
Marcelo Garrido
P304
P356
10.1016/S0140-6736(15)01281-7
P407
P577
2015-12-18T00:00:00Z